Skip to main content
Clinical Trials/NCT06105580
NCT06105580
Recruiting
N/A

Conduction System Pacing vs Biventricular Resynchronization Therapy in Systolic Dysfunction and Wide QRS: Mortality, Heart Failure Hospitalization or Cardiac Transplant

Hospital Clinic of Barcelona1 site in 1 country320 target enrollmentNovember 27, 2023

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cardiac Resynchronization Therapy
Sponsor
Hospital Clinic of Barcelona
Enrollment
320
Locations
1
Primary Endpoint
Composite end-point: all-cause mortality, cardiac transplant or heart failure hospitalization.
Status
Recruiting
Last Updated
last year

Overview

Brief Summary

Conduction system pacing vs biventricular resynchronization therapy in systolic dysfunction and wide QRS: mortality, heart failure hospitalization or cardiac transplant (CONSYST-CRT II trial).

Superiority trial that aims to study the composite endpoint consisting of all-cause mortality, cardiac transplant or heart failure hospitalization at 12-month follow-up.

Detailed Description

To date, studies have shown that conduction system pacing could get similar clinical and echocardiographic responses to those obtained with biventricular therapy. This study will randomize 320 patients to a strategy of biventricular pacing versus conduction system pacing. CONSYST-CRT II study will analyze a clinical endpoint as primary endpoint and the following parameters in both groups: left ventricular ejection fraction, ventricular volumes, echocardiographic response (\>=15% decrease in left ventricular end-systolic volume), NYHA functional class, heart failure hospitalization, all-cause mortality, cardiac transplant, QRS shortening, echocardiographic dyssynchrony (atrioventricular, interventricular, intraventricular) and global longitudinal strain. As a secondary endpoint, baseline predictors of response to conduction system pacing and biventricular pacing according to cardiac magnetic ressonance and electrocardiographic imaging will be studied. Clinical, electrocardiographic, echocardiographic follow-up will be performed during 12 months.

Registry
clinicaltrials.gov
Start Date
November 27, 2023
End Date
November 2027
Last Updated
last year
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Josep Lluis Mont Girbau

Head of Arrhythmia Research.

Hospital Clinic of Barcelona

Eligibility Criteria

Inclusion Criteria

  • Patient must indicate acceptance to participate in the study by signing an informed consent document.
  • Patient must be ≥ 18 years of age.
  • Left bundle branch block, QRS ≥130 and LVEF \<=35%. No indication of stimulation for AV block.
  • Non-left bundle branch block, QRS ≥150 and LVEF \<=35%.
  • Resynchronization therapy indication for ventricular dysfunction (LVEF \<40%) and indication of cardiac pacing for AV block.
  • LVEF \<=35% in NYHA class III or IV, atrial fibrillation and intrinsic QRS \>=130 ms, provided a strategy to ensure biventricular capture is in place.

Exclusion Criteria

  • Myocardial infarction, unstable angina or cardiac revascularization during the previous 3 months.
  • Pregnancy.
  • Participating currently in a clinical investigation that includes an active treatment.

Outcomes

Primary Outcomes

Composite end-point: all-cause mortality, cardiac transplant or heart failure hospitalization.

Time Frame: 1 year

Clinical follow-up at 12 months

Secondary Outcomes

  • Correction of interventricular dyssynchrony.(15 days; 6 months; 1 year)
  • Change in global longitudinal strain (GLS).(15 days; 6 months; 1 year)
  • Change in left ventricular ejection fraction.(6 months; 1 year)
  • Echocardiographic response.(6 months; 1 year)
  • QRS shortening.(Immediately after the intervention)
  • Correction of septal flash.(15 days; 6 months; 1 year)
  • Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Conduction velocity (cm/s).(Baseline (pre intervention). And immediately after the intervention)
  • Description of baseline predictors of response to conduction system pacing and biventricular pacing. Cardiac fibrosis quantification.(Baseline (pre intervention).)
  • Correction of auriculoventricular dyssynchrony.(15 days; 6 months; 1 year)
  • Change in left ventricular end-systolic volume.(6 months; 1 year)
  • Change in NYHA functional class.(6 months; 1 year)
  • Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Left ventricular activation time (LVAT), ms.(Baseline (pre intervention). And immediately after the intervention)
  • Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Left ventricular dyssynchrony index (LVDI).(Baseline (pre intervention). And immediately after the intervention)
  • Description of baseline predictors of response to conduction system pacing and biventricular pacing with Electrocardiographic Imaging. Ventricular electrical uncoupling (VEU).(Baseline (pre intervention). And immediately after the intervention)

Study Sites (1)

Loading locations...

Similar Trials